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Abstract: In the past two decades, more than 20 viruses with selective tropism for tumor cells
have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of
these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So
far, nine phase I or II clinical trials have been conducted or initiated using four different types
of OVs in patients with recurrent ovarian cancers. In this article, we summarize the different
OVs that are being assessed as therapeutics for ovarian cancer. We also present an overview
of recent advances in identification of key genetic or immune-response pathways involved in
tumorigenesis of ovarian cancer, which provides a better understanding of the tumor specificities and oncolytic properties of OVs. In addition, we discuss how next-generation OVs could
be genetically modified or integrated into multimodality regimens to improve clinical outcomes
based on recent advances in ovarian cancer biology.
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Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the
gynecologic malignancies.1,2 If caught at an early stage, the majority (approximately 90%)
of ovarian cancer patients are cured. Approximately 90% of ovarian tumors are epithelial
in origin, with the remainder being sex cord–stromal and germ cell tumors. These latter,
rarer tumor types of the ovary and epithelial tumors that are confined to one or both
ovaries (ie, stage 1A/B) are usually treated with surgery alone due to the early diagnosis
and lower metastatic potential. Over three-quarters of ovarian tumors, however, are
discovered at an advanced metastatic stage, when prognosis is poor.
Most other carcinomas follow a pathway of disease dissemination that involves
intravasation into the bloodstream followed by extravasation at distant tissue sites, as
well involvement of lymphatic spread.3 Metastasis of epithelial ovarian cancer is unique
in that it typically spreads by direct dissemination or shedding of cancer cells from
the primary tumor site into the ascites of the peritoneal space, followed by secondary
tumor seeding by implantation onto the serosal surfaces of abdominal organs.4,5 This
implies that there are likely molecular and cellular properties of ovarian tumor cells that
dictate this pattern of metastasis; unique properties, perhaps, that could be exploited
for more efficacious therapeutic strategies.

Heterogeneity of ovarian cancer
Epithelial ovarian cancer does not represent a single disease, but rather can be
distinguished and characterized as distinct histological subtypes.6 The four most
Oncolytic Virotherapy 2012:1 1–21
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common histotypes of epithelial ovarian cancer are serous,
endometrioid, clear cell, and mucinous; these can also be
subclassified based on grade, although clear cell is always
considered high-grade. Further to this complexity, a substantial proportion of epithelial ovarian cancer cases will be
of mixed histologies.
Over the last several years, genetics, genomics, and
gene-expression analyses have demonstrated that there are
common mutations and aberrant signaling pathways that
typify these histologic subtypes. High-grade serous ovarian
cancers almost universally harbor mutations in TP53, and
these tumor cells are defined as being highly genomically
unstable.7,8 In comparison, TP53 mutations and genomic
instability are rare in low-grade serous ovarian cancers,
but rather these tumor types commonly possess activating
mutations in KRAS and BRAF. Gene-expression analyses
have corroborated clinicopathologic definitions of these
histologic subtypes, since each subtype has a characteristic
gene-expression pattern resembling the normal cell/tissue
type.9 Serous ovarian cancer is similar to fallopian tube
epithelium, endometrioid, and clear cell to endometrial
cells, and mucinous to gastrointestinal cells of the colon.
This also reflects the argument that a subset of these ovarian
malignancies may arise from origins alternative to the ovary.
For example, a substantial amount of strong evidence directs
the putative source of high-grade serous ovarian cancer in
the secretory epithelial cells of fallopian tube fimbriae.10
Endometriosis, a common pathologic condition seen in
approximately 15% of all women, is also a potential source
for endometrioid and clear cell cancers of the ovary.11 This
heterogeneity in tumor types seen in epithelial ovarian
cancer is clinically relevant, since it is well established that
tumor aggressiveness, response to chemotherapy, and patient
prognosis are correlated with tumor type.2 There is a trend
towards rationally selecting patients for clinical trials using
targeted therapeutics based on ovarian cancer histologic
subtype;12 however, the majority of ovarian cancer patients
with metastatic disease are treated with the standard regimen
of combined carboplatin and paclitaxel. It remains to be seen
if ovarian cancer will be a cancer type that can reap further
benefits of personalized medicine through the targeting
of histologic subtypes with their underlying genetic and
biochemical defects.

Ovarian cancer–initiating cells
The cancer-initiating cell (CIC) theory maintains that a
minority of cells within a primary tumor have the unique
capacity to repopulate a heterogeneous tumor as well as
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self-renew.13 CICs are believed to commonly have a low
mitotic rate as well as express factors that can promote their
survival. Given this, CICs demonstrate resistance to chemoand radiotherapy, thus serving as a potential source for
cancer recurrence, since current chemotherapies commonly
fail to eliminate CICs.14 CICs were originally defined within
hematologic malignancies, but they have been identified in
many different solid cancers over the past decade, including
breast,15 prostate,16 colon,17,18 liver,19 pancreatic,20 brain,21
melanoma,22 and ovarian.23–25
Ovarian CICs (OCICs) have been identified by several
groups and have been isolated and characterized using a
diverse set of markers and activities. Szotek and colleagues
successfully isolated OCICs in mouse ovarian tumor cells
and from human ovarian cancer cell lines and patient ascites
by verapamil-sensitive Hoechst efflux side population (SP).24
Fitting the definition of CICs, the SP cells represented , 1%
of the origin population of cells, had more robust sphereforming and tumour-forming potential than non-SP cells, and
repopulated a heterogeneous tumor of both SP and non-SP
cells. Subsequent to this first report, other groups have
selected OCICs from human ovarian tumors by sorting for
cell surface coexpression of CD44+ and CD117+,25 CD44+ and
MyD88+,26 or CD133+ and CD117+,27 although enrichment for
stem-like cells has also been performed using CD133+28,29 or
CD24+30 alone. More recently, groups have demonstrated that
aldehyde dehydrogenase activity can define an OCIC population in combination with CD13331,32 or CD44.33 A recent study
tested 150 combinations of eight cancer stem cell markers
and found that the combination of three – CD44, CD24, and
epithelial cell adhesion molecule – exhibited the most robust
enrichment of OCICs.34 Importantly, the OCICs that have
been identified by these different methods are commonly less
sensitive to standard chemotherapeutics used to treat ovarian
cancer patients.26 Thus, if these cells are the main contributors to recurrence of resistant disease, then therapeutics that
are more efficacious at targeting and killing these progenitor
cells are of utmost importance.

Immune response in ovarian cancer
It is important to recognize and appreciate the antitumor
immune response and subsequent immune evasion by
late-stage metastatic cancers as a universal hallmark of
malignancy.35,36 The immune system is thought to play an
essential role in facilitating tumor regression in response to
chemotherapy for ovarian cancer. The presence of tumorinfiltrating lymphocytes in response to chemotherapy and
even before chemotherapy is initiated is associated with
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better prognosis for ovarian cancer patients.37,38 There have
been numerous activities to generate anticancer vaccines for
ovarian cancer,39 yet none have come to fruition. Interestingly,
a recent report has targeted OCICs via fusion with dendritic
cells as being a potential means for immunotherapy for
ovarian cancer.40,41
Late-stage ovarian tumors are believed to grow in an
immunosuppressive environment, with many key cytokines
known to stimulate an antitumor response being significantly
reduced in the hostile ascites environment during metastatic
disease progression.42 For example, transforming growth
factor-beta, which is a potent immunosuppressive factor
known to promote late-stage human cancer progression,43
is present in biologically relevant quantities in malignant
ascites.44,45 Taken together, it implies that recruiting an active
immune response is likely a critical component to effective
therapy for ovarian cancer; however, significant pathobiological hurdles would still have to be overcome.

Preclinical studies with oncolytic
viruses in ovarian cancer
Debulking surgery followed by chemotherapy using a
platinum/taxane-based regimen is the current standard of care
for ovarian cancer. However, more than 65% of patients will
eventually relapse.46 The overall 5-year survival rate for all
stages of ovarian cancer is currently less than 50%, and for
advanced ovarian cancer remains 15%–30%.1 New, more
effective therapeutic approaches for treatment of recurrent or
drug-resistant ovarian cancer remain an urgent unmet medical need. The emerging oncolytic virotherapy represents a
unique strategy and holds great promise for cancer therapy.
Oncolytic virotherapy is defined as the use of a class of nonor low-pathogenic viruses that is able to preferably replicate
in cancer cells and eliminate them in situ; for example, via
direct lysis or induction of apoptosis.47 Currently exploited
oncolytic viruses (OVs) are either naturally occurring viruses
(either human or nonhuman) that have little or no natural
pathogenicity in humans, including reovirus, myxoma virus
(MYXV), vaccinia virus (VV), measles virus (MV), vesicular
stomatitis virus (VSV), sindbis virus (SV), Maraba virus
(MRB), and echovirus type 1 (EV1), or comprise genetically
engineered viruses, including adenoviruses (Ads), herpes
simplex viruses (HSVs) or certain poxviruses. The OVs
that are currently being developed to treat ovarian cancer
are summarized in Table 1. Most recently, two related
reviews on OVs for ovarian cancer have been published, one
review outlining the current status of the clinical data from
human trials and the other focusing on OVs for gynecologic
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malignancies.48,49 In this review, we attempt to provide more
comprehensive and up-to-date summaries of the molecular
biology of ovarian cancer and the results from preclinical
and clinical studies using OVs for ovarian cancer.

General mechanisms of tumor
selectivity of OVs
The development of malignancies, namely tumorigenesis, can
be seen as an evolution of normal cells to acquire the capacity
for uncontrolled cell division and invasive capabilities that
mediate dissemination into normal organs and tissues. During this process, tumor cells acquire genetic mutations and
cellular changes that progressively interfere with tumor
cell recognition and clearance by host immune pathways.
Coincidentally, these cellular and genetic changes of the
tumor cells over normal cells also provide the molecular targets for OVs to selectively infect and replicate in tumor cells.
There are at least five general mechanisms that determine
the tumor selectivity of OVs.

Defective innate immune responses of tumor cells
The most important inducible innate antiviral defense system
in normal cells is the interferon (IFN) signaling pathway. In
normal somatic cells, virus invasion can be sensed by a variety of sentinel receptors, such as membrane-bound Toll-like
receptors or cytoplasmic sensors like the nucleic acid helicases
encoded by retinoic-acid inducible gene-I, melanoma differentiation associated gene 5, and DNA-dependent activator of
IFN regulatory factors.50 Viral infections trigger these sensor
proteins to initiate signaling cascades that trigger IFN induction and secretion from most nontransformed mammalian
cells. Secreted type I IFN then acts on both virus-infected and
uninfected cells to upregulate the expression of many antiviral
proteins. Over 200 such IFN-inducible host proteins have
been described, including members whose primary function
is to intercept the virus infection.51 One example of such an
IFN-induced antiviral protein is protein kinase R (PKR). Once
induced, PKR can then be activated by virus-derived dsRNA.
Upon activation, PKR phosphorylates and inactivates eukaryotic initiation factor 2 alpha (eIF2α), causing global inhibition
of protein synthesis of both host and viral proteins.51 IFN also
has tumor-suppression properties that are also mediated by
PKR and other IFN-stimulated proteins. Genetic defects in
the cellular IFN-response pathway, as well as other related
innate immune responses (eg, TNF induction, apoptosis, etc)
are also frequently seen in cancer cells, and these acquired signaling defects may in fact be crucial for the proliferation and
immune evasion of cancer cells.52,53 An indirect consequence
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Table 1 Oncolytic viruses in preclinical studies on ovarian cancer therapy
Oncolytic virus

Genome and structure

Genetic modification

Tumor selectivity

Refs

Adenovirus
(serotype 5)

36-kb dsDNA
nonenveloped

E1B 55-kD deletion

Aberrant p53 pathway and
aberrant mRNA transport
Aberrant Rb pathway
RGD motif insertion targeting
TS integrins
Ad5/3 chimeric capsid targeting
TS desmoglein-2
TSP-driven E1A expression
Aberrant PKR signaling or
PI3K pathway
Activated Ras-signaling pathway
Upregulation of cellular RR
Upregulation of cellular TK
Activation of VEGF-signaling
pathway
Ras-signaling pathway,
defective IFN pathway
Defective TNF/IFN pathway,
activated Akt
Activated Ras-signaling pathway

90, 91

56
60

E1A CR2 deletion
Tropism modification

Herpes simplex
virus 1 and 2

Vaccinia virus

∼150-kb dsDNA
enveloped

190-kb dsDNA
enveloped

γ 34.5 gene deletion
ICP10 deletion
Deletion of viral RR
TK gene deletion
VFG deletion
Natural attenuation

Myxoma virus
Reovirus
(serotype 3)
Measles virus

Mumps virus
VSV
Maraba virus
Sindbis virus
Echovirus type 1

92, 93
59
103, 104
68, 105–107
120, 121
127
130
133
133
136

160-kb dsDNA
enveloped
24-kb dsRNA
nonenveloped
16-kb ss(-) RNA
enveloped

None

15-kb ss(-) RNA
enveloped
11-kb ss(-) RNA
enveloped
11-kb ss(-) RNA
enveloped
12-kb ss(+) RNA
enveloped
7.5-kb ss(+) RNA
nonenveloped

Attenuated vaccine

Targeting TS CD46 receptor
Incorporation of signal-chain
antibody retargeting
TS FRα receptor
Likely defective antiviral pathway

None

Defective IFN pathway

165

Attenuated strain

Defective IFN pathway, and unknown,
IFN- independent defects in cancer cells
Targeting TS LAMR, defective
IFN pathway
Targeting TS integrin, defective
IFN pathway

174

None
Attenuated vaccine
Tropism modification

None
None

141, 142
55

200

57, 178
58, 201

Abbreviations: TSP, tumor-specific promoter; TS, tumor specific; TK, thymidine kinase; RR, ribonucleotide reductase; VEGF, vascular endothelial growth factor;
IFN, interferon; PKR, protein kinase R; TNF, tumor necrosis factor; PI3K, phosphatidylinositol 3-kinase; LAMR, laminin receptor.

of these cellular defects is to frequently convert cancer cells
to be more permissive to infection by a spectrum of OVs
that are typically more efficiently suppressed in normal
somatic cells. For example, one of the common mutations
leading to inhibition of the IFN signaling response pathway
is constitutive Ras activation caused by various mutations to
this cellular oncogene (present in approximately 30% of all
human cancers).54 Activated Ras signaling also inhibits PKR,
likely through dephosphorylation of PKR, and this in turn
promotes infection and oncolysis of Ras-activated cancer
cells by reovirus.55

levels or absent on normal cells, usually affect adherence
or migration of cancer cells, but they can also serve as the
cell-entry receptors for OVs. For instance, cancer-specific
CD46,56 67-kD high affinity laminin receptor (LAMR),57 and
integrin α2β158 are utilized by the oncolytic MV Edmonston
strain, SV, and EV1, respectively. Additionally, some OVs can
be genetically modified to retarget recombinant viruses to
cancer-specific receptors such as the integrins αvβ3 and αvβ5,
α-folate receptor (FRα), or epidermal growth factor receptor
(EGFR).59–62 All these cancer-specific surface proteins, for
example, can be found on most ovarian cancer cells.

Overexpression of viral receptors on tumor cells

Dysregulation of the tumor cell cycle

Many cancer-specific mutations result in elevated expression
of certain cell surface molecules that facilitate tumorigenesis
and/or metastasis. These molecules, often expressed at low

Mutations in tumor suppressor genes, such as p53 and Rb,
may lead to dysregulation of cell cycle and suppression of
apoptosis, creating a cellular environment favoring continued
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proliferation of the cancer cells. Some OVs have been engineered by deletion of essential viral genes involved in interaction with cellular proliferation–regulatory proteins in normal
cells, thus enabling selective replication of the OVs in tumor
cells. For example, VV constructs that have been deleted in the
viral thymidine kinase (TK) gene can only replicate efficiently
in proliferating cancer cells that highly express cellular TK but
less efficiently in normal noncycling cells with a low level of
cellular TK.63 As another example, deletion mutation of the
adenovirus E1A gene can preempt E1A interaction with Rb
protein and thus restricts the replication of the mutant virus
in cancer cells with missing or aberrant Rb.64

Tumor-specific promoter–controlled transcription
Restriction of OV replication in certain cancer cells can also
be accomplished by insertion of a tumor cell–responsive
tumor-specific promoter (TSP) that drives the expression
of viral genes essential for virus replication. TSPs that have
been tested in ovarian cancer cells include cyclooxygenase 2
(COX2), vascular endothelial growth factor receptor (VEGF),
mesothelin, midkine, survivin, the secretory leukoprotease
inhibitor, and the C-X-C chemokine receptor type 4
(CXCR4), and multidrug resistance gene 1 promoters.65–68

MicroRNA-regulated replication of OVs
The recent discovery that some specific microRNAs (miRNAs)
are specifically dysregulated in cancer cells provides a new
avenue for targeted replication of OVs in cancer cells. miRNAs
are a class of small noncoding RNA molecules that regulate
gene expression posttranscriptionally by binding to complementary sequence on mRNA targets and then blocking protein
translation via the RNA-induced silencing complex. miRNAs
whose expression is lost or greatly reduced in cancer cells have
been used to control the expression of critical viral genes of
several OVs, thereby confining OV replication to those cancer
cells.69,70 To date, however, miRNA-regulated OVs have not
yet been studied in ovarian cancer.

Ovarian cancer model systems
Established ovarian cancer cell lines have been generated
and characterized throughout the ovarian cancer literature.
Much is known regarding the genetic perturbations within
many of these lines, particularly with the recent publication
of data from genome-wide sequencing strategies.71,72 There
are also well-defined data with respect to the tumorigenic
capacity when implanted into immune-compromised mice
with respect to take rate, tumor latency, route of injection,
and combined administration of standard chemotherapeutics
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for ovarian cancer (ie, platinum agents and taxanes).73–75
There are also concerted efforts by some groups to establish
and use primary ovarian tumor cells directly from patients.
For ovarian cancer, this not only entails growing cells from
solid tumor biopsy specimens, but can be quite effectively
performed by direct culturing of metastatic ovarian cancer
cells from the malignant ascites fluid that accumulates in the
majority of women with late-stage disease.76
The widely held belief is that epithelial ovarian cancer
cells arise from lesions within the normal ovarian surface
epithelial cells;77,78 however, more recently it has emerged
that alternative origins likely exist as well. Historically,
ovarian cancer cells are compared with either primary
cultures of normal ovarian surface epithelial cells from
oophorectomy specimens or – what has been more widely
done – immortalized counterparts of these cells are used.
Ovarian surface epithelial (OSE) cells immortalized with
simian virus 40 (SV40) T antigen originally generated by
Auersperg’s group have been commonly used,79,80 and since
then human telomerase reverse transcriptase has also been
applied.81 These immortal cell lines derived show no tumorigenic characteristics in culture and in mice, but retain normal
epithelial cell properties.81,82 Additional molecular events,
such as coexpression of E-cadherin, are required for SV40 T
antigen–immortalized human OSE to acquire tumor-forming
potential.83 To address the putative fallopian tube origin of
high-grade serous ovarian cancer, efforts have been initiated
to generate fallopian tube secretory epithelial cell lines.84
Mouse models typically entail human ovarian tumor
cell line xenografts into immune-compromised mice. For
example, ES2 cells and A2780 cell lines are quite aggressive and yield robust tumor and ascites growth within a short
period.75,85 SKOV3ip1 cells are also useful for successful
intraperitoneal (IP) injection and tumorigenesis studies.86 For
using mouse models that possess an intact immune system,
there has been the development of transgenic mouse lines that
yield bilateral ovarian tumors due to SV40 T antigen expression targeted to the mouse ovarian surface epithelium.87 This
contrasts with human OSE cells immortalized with SV40 T
antigen alone, which is nontumorigenic in mice.82 In addition, there is the utility of using the ID8 transformed mouse
OSE cell line, which can establish tumors when injected into
syngeneic C57Bl/6 female mice.88

OV candidates for ovarian cancer
Adenovirus

Members of the Adenoviridae family are DNA viruses that
commonly cause mild and self-recovered upper respiratory
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tract and digestive tract infection in healthy people. There
are 57 Ad serotypes identified in humans,89 of which Ad
serotype 5 (Ad5) is most extensively studied and has been
genetically modified into various recombinant conditionally
replicative adenoviruses (CRAds) for treatment of cancer.
CRAds possess specifically engineered elements in the
viral genome that confer selective viral replication in cancer
cells but disfavor replication in normal somatic cells. The
best-known oncolytic CRAd is E1B 55-kDa gene-deleted
Ad5 mutant dl1520 (also known as Onyx-015, developed
by Onyx Pharmaceuticals).90 E1B 55 kDa protein has been
shown in vitro to bind and inactivate the cellular tumor suppressor p53 protein, thereby blocking p53-induced apoptosis.
Originally, it was believed that prevention of p53-mediated
apoptosis by E1B 55 kDa protein allowed wild-type (WT)
Ads to replicate and propagate in normal cells, and hence
Onyx-015 would only replicate in p53-defective cancer cells.
However, E1B 55 kDa protein was subsequently found also to
be involved in late viral RNA nuclear export, and this mechanism, rather than p53 inhibition, is more likely to determine
the tumor selectivity of Onyx-015.91 The effect of Onyx-015
treatment on ovarian cancer was tested in nude mice bearing
xenografted human ovarian cancer cells.92 It was shown that
Onyx-015 was able to enhance survival of animals bearing
human ovarian OVCAR3 or A2780/CP70 tumors. This finding promoted Onyx-015 entrance into human clinical trials
for ovarian cancer in early 2000.
Two other CRAds, containing a similar but not identical 24-bp deletion in the Rb-binding conserved region 2
of the E1A gene that abrogates the binding of E1A to pRb,
and designated dl922–947 and Ad5-∆24, respectively,
were developed to target tumor cells defective in the Rb
pathway.64,93 Binding of E1A to Rb is required for Ad to
drive S-phase entry and cell cycle progression for optimal
viral replication.94 Aberrant Rb pathway and consequent
abnormal G1-S checkpoint, which can complement E1A
with mutated conserved region 2 and permit the replication
of Ad5-∆24 and dl922–947 in such tumor cells, are found
in over 90% of human cancers, including ovarian cancer.95
In vitro studies have shown that compared with WT Ad5
and Onyx-015, dl922–947 induced greater cytotoxicity in
IGROV1 and OVCAR4 ovarian cancer cells and certain
other types of cancer cells.64,96 In the IGROV1 xenograft
mouse model, dl922–947 displayed potent antiovarian
tumor activity, comparable with WT Ad5.96 It has also been
shown that dl922–947 improved antitumor activities in
other cancer xenograft models, compared with Onyx-015
and WT Ad.64
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In addition to the genetic manipulation of the E1A and
E1B genes, other approaches have also been exploited to
optimize the oncolytic activity of CRAds for ovarian cancer,
including tropism modification, TSP-controlled viral replication, arming Ads with therapeutic genes, chemotherapy–Ad
combination therapy, and novel viral delivery methods.97
Tropism modification
The Coxsackie adenovirus receptor (CAR) is the main
cellular receptor for Ad5. However, CAR is expressed on
most normal human epithelial tissues and is often expressed
at lower levels on ovarian and other primary cancer cells.98,99
The large variation of CAR expression on tumor cells, at
least in part, contributes to the oncolytic inconsistence often
observed between preclinical and clinical studies using Onyx015 virus, eg, its relative ineffectiveness in the early clinical
trials for ovarian cancer. To circumvent this CAR-dependent
cell entry in order to better target tumor cells specifically,
the Ad5 capsid was genetically modified to incorporate an
RGD motif that binds to integrins αvβ3 and αvβ5, which are
highly expressed on certain cancer cells, including most
ovarian cancers. 100–102 The derivative vector, Ad5-∆24RGD, replicated and killed several different human ovarian
cancer cell lines (Hey, OV-4, and SKOV3) as efficiently
as Ad5-WT E1A-RGD, and also replicated efficiently in
ovarian cancer primary cell spheroids.59 Moreover, treatment
of CB17 severe combined immunodeficiency (SCID) mice
bearing xenografted OVCAR3 tumors showed potent
antiovarian cancer therapeutic effects. Another strategy
used to overcome the inherent CAR deficiency on most
ovarian cancer cells was to replace the Ad5 CAR-binding
motif with that from Ad3. This enabled the chimeric vector
Ad5/3 to enter cells through a CAR-independent, Ad3
receptor–dependent pathway. The Ad3 receptor, recently
identified as the desmoglein-2 protein,103 is expressed at
high levels on most ovarian cancer cells.104 When compared
with Ad5lucRGD, the replication-incompetent luciferase
(luc)-expressing Ad5/3 (Ad5/3luc) was more efficient in
transduction of cultured ovarian cancer cell lines SKOV3.
ip1, Hey, and OV-4 as well as in human primary ovarian
cancer cells isolated directly from patients.61 Both Ad5/3luc
and Ad5lucRGD were superior to WT Ad5luc in infectivity
in vitro and in a CD1 nude mice model with subcutaneous
(SC) Hey tumor xenografts following intratumoral injection
of viruses. Other in vitro studies also confirmed that
Ad5/3 modification achieved higher infectivities in ovarian
cancer cells than the mutant RGD variant.68,105 In another
study, ovarian cancer retargeting was achieved by coating
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Ads with receptor-binding antibody-conjugated polymer
that was covalently linked to Ad capsid.62
TSP-controlled Ad viral replication
With CRAds, the tumor specificity was improved using TSPs
to drive E1A expression, which allowed limited viral replication in normal cells but not in tumor cells, and reduced the
host toxicity caused by CRAds. Several TSPs (as mentioned
previously) have been tested in ovarian cancer cell lines and
in human primary ovarian cancer cells isolated from patients.
TSPs in combination with tropism modification (Ad5/3 or
RGD) have shown to have greater oncolytic activity and
significantly reduced liver toxicity in an in vitro and in vivo
ovarian cancer xenograft model, compared with WT Ad5 or
no-TSP control viruses.68,105–107
Armed CRAds
Candidate genes that have been engineered into CRAds
potentially to augment oncolytic virotherapy include cellsuicide genes, genes that modify tumor microenvironment
for enhanced viral infectivity, and immunoregulatory genes.
Onyx-015 armed with the HSV TK gene has been shown
to suppress tumor growth in the presence or absence of the
prodrug ganciclovir in the MDAH 2774 xenograft tumor
model.108 Interestingly, ganciclovir appeared to inhibit Onyx015 and reduced its tumor suppression effects. Similar results
were also seen using Ad5/3-∆24-TK virus.109 A CRAd was
engineered to carry the CXCR-4 promoter and the tissue
inhibitor of metalloproteinase 2 (TIMP2) gene that targets
cellular metalloproteinases to inhibit tumor growth and
dissemination. The resultant mutant virus, Ad5/3-CXCR4TIMP2, showed more efficient in vitro killing of ovarian
cancer cells than the unarmed viruses.67 However, the in vivo
antitumor activity of Ad5/3-CXCR4-TIMP2 remains to be
investigated.
Chemotherapy–CRAd combination therapy
Accumulating evidence indicates that chemotherapeutic
agents or radiotherapy can be combined with OVs such as
the CRAds to significantly enhance therapeutic effects in
the treatment of cancers compared with either treatment
alone. For example, the combination of Ad5/3-∆24 with
gemcitabine (a nucleoside analog), or epirubicin (a DNAintercalating anthracycline drug) resulted in greater therapeutic efficacy than either agent alone in ovarian cancer xenograft
models.110 Combination of dl922–947 with paclitaxel or
combination of the survivin promoter–containing vector
CRAd.S-RGD with cisplatin also had significantly greater
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therapeutic benefits than single-agent treatments in ovarian
cancer xenograft models.111,112 It was suggested that cisplatin and gemcitabine might act to increase viral replication,
whereas paclitaxel and dl922–947 together induced aberrant
mitotic slippage and multinucleation, leading to a more
efficient apoptotic cell death.
Enhancement of viral delivery
Ads commonly cause subclinical human infections that
usually induce protective neutralizing antibody responses in
virus-infected people. For example, approximately 40%–69%
of the adult population in the US are seropositive to Ad5.113
Preexisting anti-Ad5 antibodies in humans may reduce clinical efficacy of intratumorally injected Ad5-based vectors and
represents a serious hindrance to the clinical application
of systemically administered CRAds. Furthermore, direct
injection of Ads may also cause higher systemic toxicity
responses in patients, especially in the liver. In order to
overcome these barriers, two strategies have been developed
to enhance the therapeutic effects of Ad delivery on ovarian
cancer. The first strategy is to coat the viral particles with
liposome polymers, which would shield the antibody-binding
sites on Ad capsids from preexisting neutralizing antibodies
and also reduce antiviral humoral responses as well as liver
uptake of the virus.114,115 Using this method, liposome-coated
Ad5 armed with the antiangiogenic agent endostatin had
increased in vitro transfection capacity in SKOV3 cell lines
and also had enhanced antitumor effects in a SC SKOV3
xenograft nude mouse model when the virus was administered
through intravenous (IV) administration.116 Another strategy
for targeted delivery enhancement is to load mesenchymal
stem cells (MSCs) with Ads before viral administration. One
advantage of MSCs over other potential virus-carrier cells
is that MSCs can be readily generated from patients’ own
adipose tissues and grown to a large quantity. MSCs have
been shown to display preferable homing to ovarian tumors
after IP injection in an ovarian cancer xenograft model.117
It has also been demonstrated that Ad5/3 and Ad-RGD
viruses could efficiently infect MSCs without induction
of severe cytopathic effects.117 When tested for antiovarian
cancer effects, MSCs loaded with Ad5/3 or Ad5-D24-RGD
induced cell killing of ovarian cancer cells and significantly
suppressed tumor growth and prolonged survival in the
SKOV3 xenograft animal model.117,118 MSCs loaded with
Ad5-D24-RGD were as effective a strategy as administration
of the virus alone, but showed a dramatic decrease in systemic
spread of the virus, suggesting much less virus-associated
systemic toxicity in the treated mice.118
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Herpes simplex viruses
Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) are members of Herpesviridae, a virus family of large, enveloped,
dsDNA viruses. Both viruses infect most humans, with about
two-thirds of the adult population being seropositive for one
or both of the viruses.
HSV-1 and HSV-2 have been developed as oncolytic
agents by genetically modifying the viral genomes for more
targeted replication in cancer cells. For example, in the HSV-1
vector Baco-1, both copies of the viral γ34.5 genes encoding
the ICP34.5 neurovirulence factor were deleted and a green
fluorescent protein (GFP)-expression cassette was inserted
elsewhere in the viral genome.119 ICP34.5 recruits cellular
protein phosphatase-1α to dephosphorylate eIF2α, thereby
counteracting the PKR signaling pathway.120 ICP34.5 also
interferes with the phosphatidylinositol 3-kinase (PI3K)
pathway.121 HSV-1716, an attenuated HSV-1 mutant with
deletion of a 759-bp DNA fragment and showing ICP34.5
deficient phenotype,122 was among the first OVs to treat
ovarian cancer in animal models.123 HSV-1716 treatment
significantly suppressed tumor burden in SCID mice bearing human ovarian SKOV3 or A2780 tumors. Moreover,
treatments with PA-1 teratocarcinoma cells carrying HSV1716 showed greater antitumor activity compared with virus
treatment alone. However, HSV-1716 and other similar
HSV-1 vectors with deletion in γ34.5 genes, although showing tumor cell–killing abilities in preclinical studies, did
not significantly affect tumor growth or improve prognosis
in early clinical trials.124,125 To improve the potency of this
first generation of the HSV-1 vector Baco-1, a hyperfusogenic glycoprotein gene of the gibbon ape leukemia virus
(GALV.fus) was inserted by replacing the GFP-expression
cassette.126 When the resultant engineered HSV-1, called
Synco-2D, was compared with Baco-1 for its induced
cytopathic effects on human ovarian cancer cells Hey-8
and SKOV3 in vitro, Synco-2D produced more pronounced
syncytial formation and killed infected ovarian cancer cells
more rapidly. In nude mice bearing IP Hey-8 xenografts, IP
injection of Synco-2D resulted in 100% of mice surviving
to the end of the experiment and 75% of the treated mice
being tumor-free, whereas only 60% of Baco-1–treated mice
survived and all bore large tumors. All mice died in the control mock-treated cohort. Another engineered HSV-2 based
GALV.fus-expressing oncolytic vector was tested in ovarian
cancer. This vector, named FusOn-H2, contains an additional
modification, ie, deletion of the viral ICP10 gene. ICP10
encodes in its N-terminus a serine/threonine protein kinase
domain that can activate the Ras signaling pathway and is
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required for efficient HSV-2 replication in normal cells.127 It
was also shown that FusOn-H2 had a greater ability to eradicate tumors in nude mice bearing IP disseminated SKOV3
xenografts (more than 80%) than Baco-1 (12%). These data
suggest that oncolytic HSV armed with GALV.fus may provide
a novel therapy for ovarian cancer.
In another recent study, it has been shown that carrier
cell–based delivery of oncolytic HSV-1 mutants can improve
antitumor effects against ovarian cancer through the amplification of the viral load and avoidance of neutralizing
antibodies. This was tested using attenuated HSV-1 mutant,
Hh101, and using human peritoneal mesothelial cells as cell
carriers in a nude mice model xenografted with SKOV3 tumor
cells.128 In this model, Hh101 carried in mesothelial cells
significantly improved the antitumor activities of the virus
compared with the Hh101 virus–alone treatment. Hh101 is
an HSV-1 mutant isolated from Vero cells coinfected with
HF10, a naturally attenuated virus derived from the HSV-1
HF strain,129 and hrR3, an early generation of HSV-1 vector
deleted in UL39 gene encoding ribonucleotide reductase.130
Hh101 has also been shown to effectively treat disseminated
peritoneal colon carcinoma in a BALB/c mouse model.131
The role of host immune responses in HSV-mediated
oncolytic virotherapy has been studied. Using HSV-1716
and a syngeneic mouse model of murine ID8 ovarian cancer
cells expressing VEGF, it was demonstrated that IP injection
of HSV-1716 led to the suppression of tumor growth and
enhancement of mouse survival.132 Virus treatment–induced
infiltration of monocytes and dendritic cells to the tumor and
also upregulated the level of IFN-inducible chemokines,
including monokine-induced gamma IFN protein (called
MIG, now known as CXCL9) and IFN gamma-induced protein 10 (IP-10).132 Activated natural killer (NK) cells or CD8+
T cells were also recruited to the tumor microenvironment,
likely mediated by MIG and IP-10. In addition, tumor cells
infected with HSV-1716 expressed viral glycoproteins on
the cell surface and were highly phagocytosed by dendritic
cells, leading to induction of vaccination effects. These data
indicated that HSV-1716, and possibly other oncolytic HSV
vectors as well, exert their most oncolytic activities when
they elicit both antitumor immune responses as well as direct
killing of tumor cells.

Vaccinia virus
VV is a large enveloped dsDNA virus belonging to the
Poxviridae family. Some strains of VV used as attenuated
live-virus vaccines against smallpox have been studied as
replicating OV agents. These VV vaccines can be further
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attenuated to increase cancer selectivity by deletion of
specific viral genes. Some of these genes include the viral
TK and VV growth factor (VGF) genes.133,134 TK is critical
for VV DNA synthesis, particularly to infect normal cells,
where nucleotide pools are typically low. Deletion of the
VGF gene renders the virus defective in its ability to stimulate cell proliferation of noncycling cells to prime them for
VV infection.
The deleted TK gene is often replaced with ectopic
reporter genes (eg, luc, Escherichia coli beta galactosidase
gene lacZ, or GFP) or therapeutic genes (eg, granulocytem acrophage colony-stimulating factor [GM-CSF]) to
facilitate monitoring virus spread or to improve antitumor
activities, respectively. For example, rVV4 is a hyper-attenuated
recombinant derivative of the vaccine strain Lister of VV,
containing both lacZ and luc inserted into the TK gene.135
rVV4 has shown oncolytic efficacy in both human ES-2
ovarian cancer cells in nude mice (significant tumor reduction with no ascites accumulation and 100% of mice survived
to 70 days posttreatment; controls survived to 28 days) and
Defb29 Vegf mouse ovarian tumor cells in C57Bl/6 mice
(infection led to significant tumor necrosis and cell death,
and survival up to 63 days after treatment; controls survived
to 42 days). Another TK-deletion VV construct, JX-594, was
engineered from the Wyeth vaccine strain of VV. JX-594 also
has insertions of lacZ or luc, and expresses human GM-CSF.
This virus can infect and kill human ovarian cancer cells
in vitro and specifically infect autochthonous ovarian tumors
when injected IP into transgenic FVB/N mice expressing
SV40 T antigen driven by the Müllerian inhibitory substance
type II receptor promoter.87,136 In addition to singly TKdeleted VV, the TK and VGF double-deleted virus (vvDD)
has also been tested in ovarian cancer. vvDD has potent
oncolytic activities in mouse MOSEC cells, human ovarian
cancer cell line A2780, and human primary ovarian tumor
cells in vitro, and in nude mice bearing IP A2780 tumors.137
When vvDD was armed with a yeast cytosine deaminase
(CD) gene that can been paired with prodrug 5-fluorouracil
for enhanced chemotherapy, the resultant vvDD-CD virus in
combination with 5-fluorouracil displayed higher antitumor
activity than vvDD-CD alone in the syngeneic IP MOSEC
C57Bl/6 mouse model.137
VV combined with other therapeutic agents can also augment its oncolytic activities. Recombinant VV as an oncolytic
monotherapy requires repeated treatments; however, induced
neutralizing antibodies can potentially limit the booster effect
of subsequent inoculations, particularly in those who have
been previously vaccinated against smallpox. To circumvent
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this, cotreatment with COX2 inhibitors reduces the generation of neutralizing antibodies due to VV administration.138
Mouse ovarian tumor MOSEC cells expressing luciferase
injected into C57Bl/6 mice and treated with COX2 inhibitor exhibited higher viral titers when rechallenged with
rVV4 with significantly fewer antibodies than control mice
untreated with COX2 inhibitor. The doubly treated mice also
showed reduced tumor growth and longer survival compared
with rVV4 or COX2 treatments alone. Alternatively,
limitation of repeated administration can be circumvented
by using different OVs. It has been shown that VV injection
followed by injection of another OV, the alphavirus Semliki
Forest, or vice versa, induced longer survival than either virus
alone in C57Bl/6 mice with MOSEC IP engraftments.139
Moreover, sequential treatment of MOSEC tumor-bearing
C57Bl/6 mice with VV expressing ovalbumin and Semliki
Forest virus expressing ovalbumin induced higher CD8+
T-cell immune responses and longer animal survival than
treatment with single virus alone. These results suggest that
the efficacy of oncolytic virotherapy could be improved by
employing different OVs and combining tumor antigen–
specific immunotherapy.

Myxoma virus
MYXV is a poxvirus with a very restrictive rabbit-specific
tropism in nature but which is completely apathogenic and
safe to all non-lagomorphs tested, including mice, rats, and
humans. In vitro, MYXV has been shown to infect and kill a
wide variety of human cancer cells.140 The tumor selectivity
of MYXV depends in part on dysregulated intracellular
signaling pathways in the cancer cells, specifically the PI3K
pathway and the activation of Akt (p-AKT).141,142 An ankyrin
repeat–containing host-range protein of MYXV termed
M-T5 can directly bind to and induce the kinase activity of
Akt, which allows more robust viral replication in cancer
cells.135 Recently, MYXV has been shown to possess potent
oncolytic activity against human epithelial ovarian cancers
from both cell lines and ascites-derived primary patient cells.
OVCAR3, OVCA429, SKOV3 human ovarian cancer cell
lines, and ∼55% of patient samples tested demonstrated
susceptibility to MYXV killing in monolayer.143 In an
in vitro model of ovarian cancer metastasis, cells cultured
in ultralow attachment plates to form multicellular spheroids
(the hypothesized vehicles for ovarian cancer metastasis)
were also infected by MYXV. Spheroids formed from both
cell lines and ascites-derived patient samples that were
infected with MYXV were killed and showed decreased
reattachment upon reintroduction to adherent culture,
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thus demonstrating the potential antimetastatic properties
of this virus. The oncolytic properties of MYXV correlated
with the level of p-Akt found in specific cell culture conditions, ie, an increase in p-Akt levels in monolayer showed
greater killing, whereas decreased p-Akt levels in spheroids
had little killing until reattachment in adherent culture. Thus
it is predicted that MYXV will have particular utility for
targeting metastatic spread of this cancer, but this remains
to be tested in vivo.

Measles virus
MV is a member of the Paramyxoviridae family and is an
enveloped, single-stranded, negative-sense RNA virus that
causes rash, fever, runny nose, cough, muscle pain, and red
eyes in an infected person. A live attenuated MV vaccine
strain called Edmonston has been developed as an effective
oncolytic virus for treatment of ovarian cancer in preclinical
studies.144 Upon viral infection, the hemagglutinin envelope
glycoprotein of the oncolytic MV binds to the cellular
receptor CD46, a cofactor for inactivation of complement,
and subsequently the fusion glycoprotein induces fusion of
viral-cell membranes.56 Expression of hemagglutinin and
fusion proteins on the surface of virus-infected cells results
in intercellular fusion of multiple neighboring uninfected
cells with the infected cell, a characteristic MV-induced
cytopathic effect (CPE) called syncytia. Extensive formation
of syncytia causes apoptotic cell death of not only infected
cells but also uninfected neighboring cells, a bystander killing
that may augment the oncolytic activity of MV. CPE effects,
however, are only induced when infection takes place in
cells with more than a required minimum density of CD46
receptor expression.145 Normal cells usually express only a
low level of CD46. Therefore, infection of normal cells does
not cause CPE and cell death. The safety of oncolytic MV
has been demonstrated in measles replication–permissive
animal models, including a CD46 transgenic mouse model
and macaque models.146,147 The CD46 receptor is highly
expressed in ovarian cancer cells, rending ovarian cancer an
ideal target for MV virotherapy.148–150 A modified oncolytic
MV expressing the soluble extracellular domain of human
carcinoembryonic antigen (CEA) was created to monitor
viral replication noninvasively in vivo.151 MV-CEA was able
to kill a panel of ovarian cancer cells in vitro. Furthermore,
intratumoral injection of MV-CEA led to 80% complete
tumor regression in SC SKOV3.ip1–engrafted athymic nude
mice, and IP administration of the virus greatly enhanced
the survival of IP SKOV3.ip1 xenograft mice.144 In addition,
it was also confirmed that CEA expression could be used as

10

submit your manuscript | www.dovepress.com

Dovepress

a marker for the presence of MV-CEA replication post–viral
administration. These results provided the basis for the subsequent phase I clinical trial with MV-CEA in patients with
recurrent ovarian cancer. Interestingly, in a following study
testing multiple dosages in an IP xenograft animal model,
Peng et al reported that IP treatments with either six doses
of 103 or single or six doses of 104, 105, or 107 median tissue
culture infective dose (TCID50) MV-CEA resulted in equivalent anti-tumor effects.152 These results suggested that in vivo
tumor growth and MV infection/replication could reach an
equilibrium state regardless of the initial infection doses.
In addition to CEA, the thyroidal sodium iodide symporter
(NIS) was also inserted into the MV genome for monitoring
viral propagation, which can be mapped by serial radioiodine
imaging. Results using MV-NIS suggested that MV-CEA
and MV-NIS had comparable tumor suppression activity
in vivo.153 A more attenuated Edmonston strain–derived MV
vaccine, called MV-Moraton, and another live virus vaccine
from the Paramyxoviridae family, Jeryl Lynn mumps, have
also been investigated for their possible oncolytic activity. The
results showed that both viruses have potent antiovarian tumor
activities comparable with MV-CEA in xenograft models.154
MV-Moraton and Jeryl Lynn mumps are commercially available vaccines and have been used in more than 300 million
people. The proven safety profile in humans and the capacity
for mass production make these two viruses appealing OV
candidates for cancer therapy in general.
A tropism-modified MV has also been generated and
studied for its potential application in ovarian cancer. To
minimize potential CD46-associated immune suppression
and virus sequestration by non–target tissues after MV
administration, the hemagglutinin protein of MV was genetically modified to incorporate a single-chain antibody (scFv)
specific for FRα while eliminating its CD46 binding.60 FRα
has been found to be overexpressed in various cancers
including 90% of ovarian cancer, whereas in normal tissue,
FRα is only expressed at the apical surface of polarized epithelial cells.155,156 The recombinant virus MV-FRα reduced
its background viral infection levels on normal cells and
targeted only FRα-expressing cancer cells. The virus retained
complete antiovarian cancer activity of the parental MV, as
demonstrated in SC and IP SKOV3.ip1 xenograft models.
MSCs have also been tested as the virus-carrying vehicle
in an attempt to protect MV from preexisting neutralizing
antibody and to improve targeted delivery of the virus to
ovarian tumors. It was shown that MV-infected MSCs could
efficiently reach and infiltrate into IP SKOV3.ip1 tumors
for virus delivery in measles-naive athymic mice and also
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in mice passively immunized with human measles immune
serum.157 This resulted in effective enhancement of animal
survival in the tumor-bearing cohorts. In contrast, no such
effect was displayed when passively immunized mice were
treated with naked virus or uninfected MSCs.

Reovirus
Reoviruses are nonenveloped viruses with a genome consisting of 10–12 dsRNA segments. Reoviruses were initially
named respiratory enteric orphan viruses because they were
commonly isolated from human respiratory and gastrointestinal tracts but are not apparently associated with human
diseases. Reovirus serotype 3 Dearing strain has been developed as an OV under the trade name Reolysin (Oncolytics
Biotech).158 It is very difficult to genetically modify reovirus
using classic reverse-genetic approaches because of the
segmented dsRNA viral genome. Nevertheless, the WT,
unaltered Reolysin, has potent intrinsic oncolysis activities.
Reovirus specifically targets and kills cancer cells with an
activated Ras signaling pathway that leads to the inhibition
of PKR activation.55 In normal cells, it is believed that PKR
is activated by reovirus genomic dsRNA segments and viral
dsRNA transcripts. As a result, reovirus cannot express
sufficient viral proteins for continued replication in normal
cells, in contrast to the productive virus infection in tumor
cells that possess deficient PKR activation. It has also been
suggested that the oncolytic activity of reovirus is mediated
by TNF-related apoptosis-inducing ligand (TRAIL)-induced,
caspase 3/8-dependent apoptosis.159,160
Mutations in the Ras signaling pathway are often found
in patients with ovarian cancer,161 indicating that ovarian
cancer is a potential therapeutic target for reovirus. In an
early in vitro study, Reolysin efficiently infected and killed
four human ovarian cancer cell lines (MDAH2774, PA-1,
SKOV3, and SW626), primary ovarian cancer cells from
patient samples, but not a normal ovarian fibroblast cell
line (NOV-31).162 It was further demonstrated that intratumoral injection of Reolysin induced regression of SC
SKOV3 tumors in nude mice, and IP administration of the
virus inhibited ascites formation and prolonged survival of
treated mice in an IP MDAH2774 xenograft model. This
study also showed that Reolysin specifically and effectively
infected distal colon tumors in the SC flank, but not normal
tissue surrounding the tumor, following IV delivery of the
virus. Reolysin infection of ovarian cancer cells could also
sensitize the cells to recombinant TRAIL, an anticancer agent
currently being tested in clinical trials,163 possibly via downregulation of cellular FLICE/caspase-8 inhibitory protein.159
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This suggests that combination of reovirus and TRAIL could
be more effective than either regimen alone in the treatment
of ovarian cancer.

Vesicular stomatitis virus
VSV is an enveloped, negative-stranded RNA virus of the
Rhabdoviridae family. Viruses in this family are attractive
OV candidates, because with the exception of rabies, they
are rarely associated with diseases in humans. Moreover,
few people have preexisting immunity in most populations
worldwide.
VSV binds to and enters mammalian cells through an
unidentified receptor that is ubiquitously expressed in normal cells and malignant cells.164 Infection of normal cells
strongly induces interferon-mediated antiviral responses, and
thus virus replication is blocked. By contrast, cancer cells
frequently have defective interferon signaling pathways,
allowing for unchecked viral replication. A dysregulated
PKR pathway is the one of the key factors for determination
of the tumor selectivity of VSV.165 Viral protein expression
and replication likely kill virus-infected cancer cells by the
induction of apoptotic cell death during metaphase, which
is triggered by inhibition of mitotic progression by VSV
infection.166
It has been shown that VSV is a potent oncolytic in a wide
variety of cancer models,167 including ovarian cancer.168–170
In vitro, a VSV vector–expressing GFP (VSV-GFP) was
able to efficiently infect and kill various ovarian cancer cell
lines and ovarian surface epithelial cells transformed with
SV40 T antigen within 3 days.169 By contrast, infection of
normal primary human ovarian epithelial cells was detected
in only about 5% of the cells, and no cytotoxicity effects
were observed 3 weeks postinfection. The antiovarian cancer
efficacy of VSV-GFP has also been tested using an immunocompetent white spotting variant (Wv) mouse model.169
Wv mice have a naturally occurring point mutation in the c-kit
gene, causing defects in the development of germ cells.171,172
Nearly 100% of homozygous Wv mice develop ovarian
epithelial tumors, defined as tubular adenomas, as early as
3 months of age.173 This type of epithelial ovarian tumor is
benign, but can gain increasing neoplastic changes in older
mice. Treatment of tumor-bearing Wv mice with VSV-GFP
via intrabursal, IP, or IV administration was shown to greatly
reduce the tumor burden without inducing detectable toxicity
effects.169 Examination of GFP signals in treated Wv mice
10 days after virus injection indicated that VSV selectively
targeted the in situ ovarian tumor, while no GFP expression
was detected in any other organs and tissues. In another study,
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using an IP human ES-2 ovarian cancer xenograft model,
Stojdl and colleagues showed that a VSV virus (AV2) with
mutated matrix protein and enhanced ability to induce IFN
responses in normal cells enhanced survival of virus-treated
animals.170 AV2 has slightly decreased oncolytic activity
in ovarian cancer cells in vitro compared with WT VSV.
However, AV2 is highly attenuated in BALB/C mice, suggesting that it may be safer for clinical applications.

Maraba mirus
Like VSV, MRB is a member of the Rhabdoviridae family.
In a comparison of oncolytic activity across this family,
MRB was shown to have the highest degree of killing in
an array of cancer cell lines, including those from ovarian
sources.174 To improve replication and decrease toxicity,
two point mutations were made in MRB (MRB MG1) that
were homologous to two point mutations made in VSV that
improved replication of VSV. In an ES-2 xenograft model of
ovarian cancer, low doses of MRB MG1 showed significant
decreases in tumor burden. Moreover, there was a dosedependent tumor response to MRB MG1, and it demonstrated
better efficacy at all doses when compared directly with a
VSV construct.

Sindbis virus
SINV is a member of the Togaviridae family that is an enveloped, positive-stranded RNA virus that infects natural host
birds and transfers vector mosquitoes. Infection in humans
can occur when a person is bitten by infected mosquitoes, but
generally causes very mild symptoms. SINV as a blood-borne
pathogen is stable in the bloodstream, which may enable
more efficient systemic delivery of the virus. SINV has an
inherent tropism for tumor cells. The SINV receptor LAMR
is overexpressed in ovarian cancer cells175 and many other
types of tumor cells,176 and is important to mediate cancer cell
migration and metastasis.177 Like VSV, SINV is highly sensitive to IFN, and thus can only replicate in cancer cells with
acquired genetic defects in the IFN-signaling pathway, but
not in normal cells with intact innate immune responses.178
Productive infection, at least with VSV, likely causes cancer
cell death by inducing apoptosis.179
SINV virotherapy of ovarian cancer was first tested
using an SCID mouse model bearing IP human ES-2 ovarian
cancer xenografts and a syngeneic C57Bl/6 mouse model
with IP engraftment of murine MOSEC ovarian cancer
cells.180 It was found that IP injection of SINV significantly
suppressed tumor growth in both models. Survival analysis in the syngeneic model also confirmed the antitumor
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activities of SINV. An attenuated laboratory SINV strain,
AR339, also suppresses tumor growth in a human OMC-3
ovarian cancer xenograft model.181 By using in vivo imaging
of SINV expressing firefly luciferase and ES-2 cells expressing Renilla luciferase, combined with histologic analysis,
virus infection colocalized with the tumor tissue in vivo,
suggesting that virus infection is tumor-specific. In addition
to the oncolysis of cancer cells, SINV also was also shown
to induce a potent bystander antitumor immunity.178 This
antitumor immunity is likely mediated by activation of NK
cells.182 Correspondingly, SINV oncolytic vectors expressing interleukin (IL)-12 or IL-15, two cytokines known to
elicit antitumor activity by activation of natural killer cells,
exhibit more potent antitumor activity than SINV expressing lacZ.180,182

Echovirus type 1
EV1 is a nonenveloped, single-stranded, icosahedral RNA
virus of the Picornaviridae family. EV1 is isolated from the
gastrointestinal tract and causes no or mild upper respiratory
infection. The EV1 receptor integrin α2β1 is highly expressed
on ovarian cancer cells, but is only present on normal surface
epithelium at a low level.183 In vitro, EV1 induces strong
cytopathic effects in various ovarian cancer cell lines, but
not in immortalized human OSE cells or human peripheral
blood mononuclear cells.184 EV1 can also infect and kill
multicellular spheroids of ovarian cancer cells DOV13.
When tested in SCID mice bearing OVHS-1 xenografts, both
intratumoral and IP injections of EV1 were shown to suppress
tumor burden significantly. In an SC xenograft model, none
of EV1-treated mice reached experiment end points (tumors
exceeding 20% of body weight) after the experiment was
ended 14 weeks post–virus administration, whereas all mice
without virus treatment reached end points within 3 weeks.
These results suggest EV1 is also a potential oncolytic virus
candidate for the treatment of ovarian cancer.

Clinical applications
Clinical studies using OVs to treat ovarian cancer is still in its
infancy. As of April 2012, results from three phase I clinical
trials in ovarian cancer have been published, involving Onyx015,185 Ad5-∆24-RGD,186 and measles virus MV-CEA.149
A phase I clinical trial testing JX-594 in patients with different types of cancers including ovarian cancer has also been
published.187 Ad5-D24-GMCSF and Ad5/3-D24-GMCSF
have also been evaluated under compassionate use regulated
by the Finnish Medicines Agency FIMEA.188,189 In addition,
there are two ongoing trials with Reolysin in ovarian cancer
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and one ongoing trial with attenuated VV GL-ONC1 for
all peritoneal metastatic cancers including ovarian cancer,
according to the NIH website ClinicalTrials.gov. Although
early phase trials mainly address the safety, maximum tolerated dose, and toxicity spectrum of OVs, antitumor efficacy,
viral replication, and antibody responses are also analyzed.
Clinical efficacies are assessed by Response Evaluation
Criteria in Solid Tumor (RECIST) criteria and cancer antigen
(CA)-125 response. CA-125, also known as mucin 16, is a
protein biomarker for recurrence of ovarian cancer.190 In all
studies, eligible ovarian cancer patients have persistent or
recurrent ovarian cancer, fallopian tube cancer, or primary
peritoneal cancer after prior treatment with chemotherapy.
The enrollees are older than 18 years and have adequate
organ function. Participating patients, except for those in
the JX-594 trial, receive administration of OVs through an
IP catheter. All these clinical studies have shown that OVs
were well tolerated, and no maximum tolerated doses were
reached in any of the trials. Encouraging antitumor responses
were observed in all but the Onyx-015 trial. Summaries of
the clinical studies are provided in Table 2.

Onyx-015
The first human OV trial for ovarian cancer was conducted
with adenovirus Onyx-015 in 16 patients.185 Four dose levels
of virus (1 × 109, 1 × 1010, 3 × 1010, and 1 × 1011 plaqueforming units [pfu]) were tested in this trial. For a particular
dose level, Onyx-015 was administered to patients daily for
5 days (one cycle) every 4 weeks. These patients received a
total of 35 cycle treatments, with a mean of two cycles per
patient. Most patients experienced common toxicity criteria
grade 1 or 2 flu-like syndrome and abdomen pain after virus
infusion. Only one patient who received 1 × 1010 pfu exhibited

common toxicity criteria grade 3 abdominal pain and grade 3
diarrhea, and the patient’s toxicity profile was considered
dose-limiting. No grade 4 toxicity was noted in any patient.
This toxicity study indicates that Onyx-015 administration
is safe at the highest dosage tested. Viral DNA was detected
10 days after the last dose of virus in five of eight patients
who were subjected to polymerase chain reaction (PCR)
testing of peritoneal specimens. No viral DNA was detected
in the blood samples in these patients. Interestingly, viral
DNA was still detected in one patient 354 days after final
virus treatment. These data, however, were not sufficient
to prove the presence of viral replication since an increase
in viral genome copy number was not shown. Antiadenovirus
antibody responses were evident in 12 of 13 patients that
were examined. Unfortunately, there was no clear evidence
of antitumor activities induced by Onyx-15 in this trial. Four
of the 16 patients showed brief stable disease after more
than two cycles of Onyx-015, but soon developed progressive disease. Eventually, all patients stopped virotherapy
because of development of progressive disease, except one
who was removed from the trial due to Onyx-015 doselimiting toxicity.

Ad5-∆24-RGD
The tropism-modif ied Ad5-∆24-RGD virus has been
engineered to improve cancer-targeting and the oncolytic
activity of early adenovirus vectors, such as Onyx-015,
in preclinical studies. Consistently, a phase I clinical trial
with Ad5-∆24-RGD has yielded promising antiovarian
cancer responses.186 In this clinical trial, vector dosages of
Ad5-∆24-RGD ranging from 1 × 109 viral particles per day
(vp/d) to 1 × 1012 vp/d, with increase of 1/2 log vp/d in each
successive cohort tested in 21 patients, of whom 18 patients

Table 2 Summaries of clinical trials of oncolytic virotherapy in patients with ovarian cancer
Virus type

Name

Study
phase

Number
of patients

Efficacy
Best responses

CA-125

MV
Ads

MV-CEA
Onyx-15
Ad5-∆24-RGD
Ad5-∆24-GMCSF
Ad5/3-∆24-GMCSF
JX-594
GL-ONC1
Reolysin
Reolysin (with paclitaxel)

I
I
I
CU**
CU**
I
I/II
I
II

21
16
21
4* (20)
4* (21)
2* (23)
Recruiting
Recruiting
Recruiting

14 SD
No clear response
15 SD
1 CR, 1 SD, 1 MR
1 SD
2 SD

5 PR
No response
7 MR
1 CR, 1 PR, 1 SD
1 MR

VV
Reovirus

Toxicity

Refs

Mild
1 DLT, 15 mild
Mild
Mild
Mild
Mild

149
185
186
188
189
187
193
194
195

Notes: *Number of patients with ovarian cancer, out of the total number of patients with various types of cancer, indicated in the parentheses, in the corresponding clinical
trial; **studies under compassionate use regulated by the Finnish Medicines Agency FIMEA. With regard to CA-125 tumor markers, MR, PR, SD, and CR indicate a less than
29% decrease, a more than 30% decrease, stabilization, and a normal level in tumor marker, respectively.
Abbreviations: CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PD, progressive disease; CU, compassionate use.
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had recurrent ovarian cancer. Virus was delivered daily for
3 consecutive days, and the patients were followed up on days
0–3, 7, 14, and 28 to evaluate toxicity, virus replication, and
antitumor efficacy. As for the clinical study with Onyx-015,
Ad5-∆24-RGD treatment did not cause significant toxicity.
Although no partial or complete responses were observed,
15 patients (71%) were shown to have stable disease.
In addition, seven patients (33%) had deceased CA-125
levels, and four of them had .20% reduction. RGD-specific
viral DNA was detected in ascites in 16 of 21 patients by
quantitative real-time (qRT) PCR after virus treatment.
More importantly, increased viral DNA copy number was
detected at various time points after day 3 of virus treatment
in seven patients, suggesting viral replication in the cancer
cells. Immunohistochemistry analysis of ascites from selected
patients confirmed the infection of ovarian cancer cells by the
virus. Dose-dependent antiadenovirus neutralizing antibody
response was generally detected in ascites and serum in all
patients. Unlike Onyx-015, Ad5-∆24-RGD DNA was also
found in serum (ten patients), saliva (ten patients), and urine
(nine patients), probably due to high replication activity of
Ad5-∆24-RGD in the IP cavity, leading to the dissemination
of the virus.

MV-CEA
MV-CEA has been tested in 21 patients with recurrent ovarian cancer in a phase I trial study.149 Patients were treated
with seven escalating doses of MV-CEA (103–109 TCID50
at 1-log increments) every 4 weeks for up to six cycles. No
dose-limiting toxicity was observed with MV-CEA. Most
toxicities were grade 1 or 2 fever, fatigue, and abdominal
pain. Fourteen of the 21 patients (67%) had stable disease
with median duration of 92.5 days. Nine of the 14 patients
with stable disease (64%) were in the three highest dose levels, indicating dose-dependent outcomes. CA-125 levels were
demonstrated to decrease .30% in five patients. Median
overall survival of the patients in this trial was 12.15 months,
while in similar patient populations the median survival is
expected to be 6 months. Viral DNA was detected in the
blood in four patients by qRT-PCR, but no virus shedding
was detected in saliva and urine in any patient. CEA levels
were elevated in the peritoneal fluid in one patient in the
108-TCID50 cohort and two in the 109-TCID50 cohort, and in
the serum in all three patients in the 109-TCID50 cohort. No
antibody responses to MV-CEA were observed. This might
have resulted from preexisting high baseline anti-measles
antibody in enrolled patients who were required to be immunized with measles for safety consideration in this first-ever
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human virotherapy trial with MV. Since MV predominantly
utilizes the CD46 receptor for cell entry, the authors also
examined the expression of CD46 in tumor specimens in
15 patients whose tissues were available, attempting to
investigate the effect of CD46 expression on the oncolytic
activities of MV-CEA. Thirteen of the 15 patients showed
high-level expression of CD46; however, no association of
CD46 expression with clinical efficacy was observed. Due
to the small patient sample size and different dosages used in
this initial clinical trial, whether CD46 expression is associated with clinical efficacy remains to be identified.

Ad5-D24-GMCSF and Ad5/3-D24GMCSF
Two phase I clinical trials have been conducted to test
whether GM-CSF could facilitate induction of antitumor
immunity in the context of oncolytic Ad vectors Ad5-∆24
and Ad5/3-∆24.188,189 Twenty patients with 15 different types
of cancers (four patients with ovarian cancer) and 21 patients
with twelve different types of cancers (four patients with
ovarian cancer) were treated with Ad5-D24-GMCSF and
Ad5/3-D24-GMCSF, separately. Viruses were administered
using ultrasound-guided intratumoral injection or intracavity
injection as in ovarian cancer patients, with one-fifth of the
dose given IV. The starting dose of virus was 8 × 109 vp/d in
the Ad5-D24-GMCSF trial, 8 × 1010 vp/d in the Ad5/3-D24GMCSF trial, and escalated to 4 × 1011 vp/d in both trials.
Both studies showed that virus treatments were well tolerated
and induced antitumoral and antiviral immune responses, as
measured by the activation of tumor- and virus-specific cytotoxic T lymphocytes. Clinical benefits were also observed in
some patients, including four patients with ovarian cancer
in the Ad5-D24-GMCSF trial and one of four patients in the
Ad5/3-D24-GMCSF trial.

JX-594
Taking the lead that VV has adapted to acquire stability in the
bloodstream and is capable of rapid spread to distal tissues,191
a phase I clinical trial was designed to test whether JX-594
could target metastatic tumors via IV infusion. Escalating
dosages (1 × 105–3 × 107 pfu/kg) were administered in
23 patients with nine different types of cancers, including
two patients with recurrent ovarian cancer.187 Results from
this study showed that JX-594 could selectively infect
tumors after IV infusion in a dose-dependent manner. Viral
infection of tumors was detected in all eight patients receiving the two highest doses of JX-594, but in only two out of
15 patients receiving lower doses. Antitumor activities were
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also observed and appeared to be dose-dependent. One of
the two patients with ovarian cancers receiving a lower dose
of JX-594 was virus-negative in tumor but showed stable
disease for more than 4 weeks after treatment. The other
patient receiving the second- highest dose was virus-positive
in the tumor and had stable disease for more than 16 weeks.
The most common virus-associated adverse side effect was
grade 1/2 flu-like symptoms, indicating that it is safe to
administer JX-594 via this IV route.

GL-ONC1
GL-ONC1 (also named GLV-1h68) is an attenuated Lister
strain VV with insertion of Renilla luciferase-GFP fusion
gene, lacZ and β-glucuronidase reporter genes in the
F14.5L, J2R (TK), and A56R (hemagglutinin) loci of the
viral genome.192 This OV is being tested in a phase I/II trial
in patients with advanced peritoneal cancers, which include
ovarian cancer patients.193

Reolysin
The two ongoing Reolysin clinical trials are (1) a phase I trial
in patients that did not respond to platinum chemotherapy,
and (2) a phase II trial to investigate the safety and efficacy
of Reolysin in combination with paclitaxel compared with a
paclitaxel regime alone.194,195 In the first clinical trial, patients
were treated with Reolysin via both IV and IP routes. Among
the patients that have been treated, viral replication could be
detected in peritoneal and ovarian cancer cells following IV
administration.196 This is the first to reveal that reovirus can
reach peritoneal and ovarian cancer via systemic delivery.

Conclusions
The use of live viruses specifically to kill cancer cells dates
back as early as the beginning of the last century.197 However,
the field of oncolytic virotherapy did not truly expand as
a systematic inquiry until two decades ago, when genetic
approaches were first applied to modify OVs in order specifically to target cancer cells.63,90 In 2005, Ad vector H101
was approved in China as the world’s first approved OV
for treatment of head and neck cancer in combination with
chemotherapy.198 Currently two oncolytic viruses, Reolysin
and OncoVEX, a herpex simplex type 1 virus–based oncolytic therapeutic agent, have entered pivotal phase III trials.
JX-594 is also being tested in phase II clinical trials for liver
cancer and metastatic colorectal cancer, and has shown great
promise in preliminary results. Early last year, OncoVEX
was acquired by Amgen in a deal that has been valued at up
to US$1 billion. Although promising, we are still far from
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fulfilling the great potential of oncolytic virotherapy. One
key challenge is our as-of-yet modest understanding of the
multifactorial interactions between the tumor, its microenvironment, OVs, and the host immune responses to both the
OV and the cancer cells.
Although preclinical and clinical studies have confirmed
the safety and potential of OV therapy for ovarian cancer,
many key outstanding questions remain to be addressed.
1. How can targeted delivery of OVs to ovarian tumor tissue be improved? Preexisting antiviral antibodies and
OV-induced immune responses to the virus can hinder
the delivery of OVs to ovarian tumor sites. The carrier
cell–based delivery strategy may overcome this hurdle,
for example when tumor-homing MSCs are used to ferry
virus to tumor tissues. The feasibility of this “Trojan
horse” approach to virus delivery in the clinical setting
remains to be tested.
2. What are the operative mechanisms for OV-mediated
antiovarian cancer effects? The parameters that determine
the susceptibility of individual ovarian cancer patients to
virotherapy is still not clear in clinical settings. In addition, few studies have addressed the complex interactions
between OVs and the various transformed and noncancerous cells that inhabit all tumor microenvironments.
Most importantly, the effects of residual or dysfunctional
antitumor immunity and the immune-evasion strategies
by ovarian carcinoma cells on the oncolytic efficacy have
not been clearly elucidated. Numerous lines of evidence
have indicated that host immunity acts as a “double-edged
sword” in oncolytic virotherapy. On one hand, the rapid
generation of host immune responses to the virus could
preempt the time window for effective viral replication
within the tumor bed. On the other hand, virus–tumor
interactions can also liberate immune responses against
tumor antigens and induce long-lasting bystander antitumor immunity. A major unanswered question remains:
does the direct killing of cancer cells by OVs or the
virus-induced antitumor immunity play the major role in
OV-induced cancer regression?
3. Can OVs target the more drug-resistant OCICs? The
ability to target chemotherapy-resistant OCICs might
determine the outcome of any new treatment for advanced
ovarian cancer, particularly in combination with standard
chemotherapies. So far, OVs have not been tested for their
capability to infect and kill OCICs.
4. How can the oncolytic potency of OVs be improved?
First, OVs in combination with chemotherapy have
shown synergistic effects in treating ovarian cancer in
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cell culture and animal models. Traditionally, OVs always
enter clinical trials not as the first-line treatment but as a
final-stage salvage attempt. Instituting earlier combination
regimens of OVs with conventional therapeutics may be
a far better strategy than testing OV monotherapy after
standard treatments have already failed. Also, sequential
employment of genetically different OVs for virotherapy
has been shown be more effective to induce antitumor
immunity in preclinical studies.139 This approach leverages the observation that different OVs have very distinct
tumor selectivities, which may facilitate targeting the cell
heterogeneity associated with many cancers, including
ovarian cancer.
5. Finally, preclinical studies have also indicated that
many OVs can be armed with efficacy-improving
therapeutic genes. These adjunct genes can express
immunoregulatory factors such as IL-12 and GM-CSF
that can stimulate antitumor immunity by activating NK
and CD8+ T cells. JX-594 and OncoVEX, being tested
in clinical trials, are both armed with GM-CSF. It is
worth noting that most current approaches aim to boost
antitumor immune responses in cancer virotherapy by
activating effector immune cells such as NK and CD8+
T cells. However, immunotherapy for cancer, particularly
ovarian cancer, has increasingly focused on inhibiting
regulatory T cells (Tregs) that block the development of
effective T-cell immune responses to tumor antigens.199
Circulating or tissue-resident Tregs may block effective
antitumor immune responses in late-stage ovarian cancer,
creating an effective immunosuppressive environment
in the tumor. New strategies to combine OVs with Tregtargeted suppression could be a key to achieve complete
regression of patients with ovarian cancer. OVs are an
ideal vehicle to deliver locally therapeutic gene products
that could assist in mounting more effective cellular
antitumor responses. Alternatively, OVs can be combined
with drugs that inhibit Tregs, such as cyclophosphamide.
In addition to its direct cytotoxic effect on cancer cells,
gemcitabine has also been shown to eliminate Tregs selectively, and preclinical models indicate that gemcitabine
can synergize well with many OVs.
In many ways, the current state of oncolytic virotherapy is
similar to the situation with the cytotoxic chemotherapy drugs
first developed over half a century ago, with one notable
exception. Like the older cytotoxic drugs still being used
routinely in the clinic today, many OVs also exhibit potent
anticancer properties in the preclinical setting, but there is
a limit to what can be learned in animal models, and their
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correct exploitation in cancer patients now requires appropriate clinical trials to teach oncologists how to exploit them
effectively. In stark contrast to the classic chemotherapeutics
that now comprise the standard of care for so many cancers,
the single most notable characteristic of OV therapies tested
to date is their extraordinary safety record. This should
encourage the oncology field to be optimistic that exploiting
the great potential of oncolytic virotherapy now needs to be
conducted in the clinical arena. Despite the challenges ahead,
advances in our understanding of tumorigenesis, antitumor
immunity, and molecular biology and anticancer properties
of OVs have helped and will continue to shape the translation of preclinical and clinical studies into significant clinical
outcomes for cancer patients.
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